Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Lei Zhou
Institution:
Jiangsu Hengrui Medicine (China)
Observed institution:
Jiangsu Hengrui Medicine (China)
ORCID:
0009-0007-9839-8449
Observed ORCID:
0009-0007-9839-8449
OpenAlex ID:
A5112870684
SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
·
Molecular Cancer Therapeutics
·
2
Supplementary Table S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S8 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Data from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S3 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S4 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S5 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S2 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S6 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Table S1 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Supplementary Figure S7 from SHR-2005, an FcγR-Dependent CD40 Agonistic Antibody with Potent Antitumor Activities and Favorable Safety Profile
2025
·
Li-Min Wang
, Changyong Yang
, et al.
Show more works
View as search
Works count:
17
Citation count:
2
H-index:
1
I10-index:
Year
Topic
Type